Eur Rev Med Pharmacol Sci 2023; 27 (7): 2987-2993
DOI: 10.26355/eurrev_202304_31931

10-month retrospective study on compliance and tolerability of the drospirenone-only pill

S. Palacios, E. Colli, M.V. de Diego, P.-A. Regidor

Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain. pedro-antonio.regidor@exeltis.com


OBJECTIVE: The current study evaluated menstrual bleeding profiles, compliance and tolerability in women using a drospirenone (DRSP)-only pill.

PATIENTS AND METHODS: This is a non-interventional, retrospective, multi-center study on healthy female adults [n=276, aged between 18 and 53 years and premenopausal using a DRSP-only pill for at least six months with a mean duration of 10.4 months (+/-SD 4.0) months]. 75.6% used other contraceptives than POP before starting with the DRSP-only pill. A questionnaire was used to evaluate the bleeding profile. 56.5% of the women had associated cardiovascular risk factors.

RESULTS: Two hundred and sixty-two (262) women (mean age of 32.5 ± 9.1 years; mean BMI of 23.1 ± 3.8 kg/m²) were eligible for analysis. 42.6% of the users had a scheduled bleeding, 33,3% unscheduled bleeding and 48% no bleeding during the last evaluable cycle. 75.4% evaluated the bleeding profile in the last cycle as very good or good, 13.8% said there was no change since starting the medication, 8.4% declared the profile was bad and 2.3% as very bad. 87.8% of the users evaluated the general satisfaction of the contraception as very good or good, whereas only 8.8% and 3.4% said there was no change or that it was bad. No women evaluated the general satisfaction as very bad.

CONCLUSIONS: These data demonstrate that the DRSP-only pill is associated with a very high satisfaction as a contraceptive in general and in the individual bleeding profile. These aspects reaffirm the acceptability not only in women with cardiovascular risk factors.

Free PDF Download

To cite this article

S. Palacios, E. Colli, M.V. de Diego, P.-A. Regidor
10-month retrospective study on compliance and tolerability of the drospirenone-only pill

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 7
Pages: 2987-2993
DOI: 10.26355/eurrev_202304_31931